ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,235.00
-0.32%
S&P ASX All Technology
3,849.60
-0.26%
Brent Oil
74.015
0.53%
US Dollar vs AUD
1.60523
-0.09%
Bitcoin
92,937.11
-0.62%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. AMEX
  6. IGC Pharma Inc (IGC)

  7. IGC Pharma Inc (IGC) News

IGC

IGC Pharma (IGC)

IGC Pharma Inc
Date:
Sort by:
 Showing the most relevant articles for your search:AMEX:IGC
DateTimeSourceHeadlineSymbolCompany
26/11/202400:30Business WireIGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's TreatmentAMEX:IGCIGC Pharma Inc
13/11/202408:04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:IGCIGC Pharma Inc
28/09/202406:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:IGCIGC Pharma Inc
28/09/202406:05Edgar (US Regulatory)Form 8-K - Current reportAMEX:IGCIGC Pharma Inc
18/09/202422:00Business WireIGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's TreatmentAMEX:IGCIGC Pharma Inc
04/09/202422:00Business WireIGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's DiseaseAMEX:IGCIGC Pharma Inc
27/08/202409:00Business WireIGC Announces Results of its 2024 Annual Stockholders MeetingAMEX:IGCIGC Pharma Inc
22/08/202423:00Business WireIGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's DiseaseAMEX:IGCIGC Pharma Inc
20/08/202422:00Business WireIGC Pharma Expands Drug Portfolio to Metabolic Disorders with IGC-1A, A Potential New GLP-1 AgonistAMEX:IGCIGC Pharma Inc
15/08/202406:23Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]AMEX:IGCIGC Pharma Inc
09/08/202411:30Business WireIGC Pharma Reports First Quarter Fiscal 2025 ResultsAMEX:IGCIGC Pharma Inc
08/08/202406:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:IGCIGC Pharma Inc
03/08/202404:38Edgar (US Regulatory)Form 8-K - Current reportAMEX:IGCIGC Pharma Inc
18/07/202423:00Business WireIGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price TargetAMEX:IGCIGC Pharma Inc
10/07/202404:17Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialAMEX:IGCIGC Pharma Inc
09/07/202423:10Business WirePreclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety ProfileAMEX:IGCIGC Pharma Inc
09/07/202406:07Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsAMEX:IGCIGC Pharma Inc
25/06/202423:00Business WireIGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's DiseaseAMEX:IGCIGC Pharma Inc
25/06/202409:30Business WireIGC Reports Financial Results for Fiscal Year Ended March 31, 2024AMEX:IGCIGC Pharma Inc
18/06/202423:00Business WireIGC Pharma to Participate in Fireside Chat with Ascendiant Capital MarketsAMEX:IGCIGC Pharma Inc
10/06/202423:00Business WireIGC Pharma Publishes Study in European Society of Medicine Investigating the Impact of CYP2C9 Genetic Polymorphism on Pharmacokinetics of Delta 9 TetrahydrocannabinolAMEX:IGCIGC Pharma Inc
28/05/202423:00Business WireIGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1AMEX:IGCIGC Pharma Inc
22/05/202411:20Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipAMEX:IGCIGC Pharma Inc
22/05/202404:00Business WireIGC Pharma to Attend BIO International Convention 2024AMEX:IGCIGC Pharma Inc
14/05/202411:54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:IGCIGC Pharma Inc
14/05/202411:53Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesAMEX:IGCIGC Pharma Inc
16/04/202421:00Business WireIGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week TwoAMEX:IGCIGC Pharma Inc
09/04/202423:00Business WireIGC Pharma Adds Advisor in Artificial IntelligenceAMEX:IGCIGC Pharma Inc
27/03/202406:00Business WireIGC Pharma Announces $3 Million Unregistered Private Placement of its Common StockAMEX:IGCIGC Pharma Inc
21/03/202402:00Business WireIGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s AgitationAMEX:IGCIGC Pharma Inc
 Showing the most relevant articles for your search:AMEX:IGC

Your Recent History

EU
EKI
Ekinops
LSE
41NW
Severn T.6q%bd
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads